ArQule sells off cancer drug rights to Basilea

After a late-stage clinical setback last year, ArQule will trade rights to its lead candidate for some upfront cash.

By Lisa LaMotta • April 18, 2018

Sanofi nears deal to sell EU generics unit for $2.4B

The French drugmaker's decision to divest the business is yet another sign of the pressures facing the generic drug industry.

By Ned Pagliarulo • April 17, 2018

Is 'BerkshAmazMorgan' testing a cure for what ails US healthcare?

This merger just might be a new healthcare model in the making, one that leverages consumer data to deliver real change on the employee health and wellness front while remaking the way that healthcare is paid for.

By Paul Darling and Pratap Khedkar • April 17, 2018

Kineta, Roche's Genentech strike chronic pain deal

Kineta's first big pharma deal could speed development of a potential disease-modifying pain drug.

By Suzanne Elvidge • April 16, 2018

Shire's oncology exit weighs on potential Takeda bid

Analysts expect a $2.4 billion deal with Servier to give Shire more negotiating power with Takeda, but it likely won't keep the suitor at bay.

By Jacob Bell • April 16, 2018

Prescribed Reading: Novartis ups the ante in gene therapy, while GSK folds on the space

Big pharmas are placing their bets on the future of gene therapy, with one European company going all-in and another pulling out.

By Lisa LaMotta • April 13, 2018

Alexion broadens pipeline with $855M Wilson Therapeutics buy

The deal hands Alexion WTX101, a candidate in Phase 3 testing for a rare genetic condition called Wilson's disease.

By Jacob Bell • April 11, 2018

Novartis buys AveXis for $8.7B, broadening gene therapy bet

Acquiring the U.S. biotech and its late-stage candidate for spinal muscular atrophy is new CEO Vas Narasimhan's first major deal as Novartis chief.

By Ned Pagliarulo • April 9, 2018

Ferring picks up microbiome specialist Rebiotix

The Swiss pharma brings in a microbial approach to C diff. infections by buying a microbiome pipeline.

By Suzanne Elvidge • April 6, 2018

Autolus pairs up with Miltenyi to manufacture T-cell therapies

Autolus aims to automate its cell processing steps utilizing Miltenyi tools, which could in theory make the complex manufacturing process more reproducible.

By Randi Hernandez • April 5, 2018

Boehringer joins checkpoint inhibitor race with OSE deal

In a heavily back-ended agreement, Boehringer is betting on a second wave of I/O drug development through the exploration of targets other than PD-1/L1.

By Ned Pagliarulo • April 5, 2018

Novo charts course for sickle cell amid headwinds in hemophilia

The Danish drugmaker lined up $400 million for access to a young biotech's investigational therapy.

By Jacob Bell • April 5, 2018

Lilly's next diabetes play would have patients implanted with engineered stem cells

In addition to an equity investment and $63 million upfront, Lilly's latest deal dangles $410 million in milestones to Sigilon Therapeutics.

By Jacob Bell • April 4, 2018

Pfizer inks deal handing CAR-T assets to newly launched biotech

The new biotech, which will be 25% owned by Pfizer, will be headed by former Kite execs looking to find success in developing allogeneic CAR-T therapy.

By Randi Hernandez • April 3, 2018

Walmart reportedly in early talks to acquire Humana

The companies already partner on Medicare Part D drug plans. But a deal could boost Humana's group market offerings to compete with other insurers, suggests one analyst.

By David Lim • April 2, 2018

Eisai partners with Nichi-Iko in generics pact

Under the deal, Eisai will transfer ownership of its generics unit to Nichi-Iko, supplying its new partner with API from a manufacturing plant in India.

By Ned Pagliarulo • March 29, 2018

Celgene, bluebird revise deal to co-develop CAR-T therapy

The market doesn't seem impressed by the updated agreement between the companies.

By Suzanne Elvidge • March 29, 2018

Takeda eyes Shire takeover

The Japanese pharma has until April 25 to announce whether it intends to submit a formal offer for the Irish specialty pharma.

By Jacob Bell • March 28, 2018

GSK buys Novartis stake in consumer business for $13B

Days after dropping its bid for Pfizer's consumer unit, GSK solidified full ownership of a joint venture set up in an asset swap with Novartis.

By Ned Pagliarulo • March 27, 2018

Prescribed Reading: AbbVie disappoints; Regeneron deals in genes

Investors questioned AbbVie's strategy in oncology after a clinical miss. Elsewhere, Regeneron partnered with Alnylam to probe the potential of a genetic discovery.

By Lisa LaMotta • March 23, 2018

Regeneron, Alnylam partner to turn discovery into new drugs for NASH

Scientists at Regeneron's labs found a genetic variant linked to lower risk of liver disease — a target that could be ideally suited for Alnylam's RNAi tech.

By Ned Pagliarulo • March 22, 2018

SemaThera inks deal for China and Japan

A diabetes eye drug deal pushes SemaThera towards the Asian market and provides financing for clinical trials. 

By Suzanne Elvidge • March 22, 2018

Celgene picks up early neuro drugs in Prothena deal

A $150 million upfront payment gives Celgene access to three candidates, boosting its presence in Alzheimer's and other neurodegenerative diseases.

By Lisa LaMotta • March 21, 2018

Mundipharma inks third biosimilar deal with Celltrion

The European conglomerate will commercialize the South Korean company's copycat version of Herceptin.

By Lisa LaMotta • March 20, 2018

Novartis taps Harvard tech to advance cancer immunotherapy efforts

Outside of cell therapy, Novartis trails in immuno-oncology. But, as its deal with Harvard shows, it aims to lead in developing second-generation approaches. 

By Randi Hernandez • March 20, 2018